Evidence map›Paper›PMID 25450398›Full record

ArticleBiochemical and biophysical research communications2014

Intracellular modifiers of integrin alpha 6p production in aggressive prostate and breast cancer cell lines.

Apollo D Kacsinta, Cynthia S Rubenstein, Isis C Sroka, Sangita Pawar, Jaime M Gard, Raymond B Nagle, Anne E Cress

Abstract read
In one paragraph

Article in Biochemical and biophysical research communications, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Apollo D KacsintaUniversity of Arizona Cancer Center, University of Arizona, Tucson, AZ, United States; Cancer Biology Interdisciplinary Graduate Program, University of Arizona, Tucson, AZ, United States.
Cynthia S RubensteinUniversity of Arizona Cancer Center, University of Arizona, Tucson, AZ, United States; Cancer Biology Interdisciplinary Graduate Program, University of Arizona, Tucson, AZ, United States.
Isis C SrokaUniversity of Arizona Cancer Center, University of Arizona, Tucson, AZ, United States; Cancer Biology Interdisciplinary Graduate Program, University of Arizona, Tucson, AZ, United States.
Sangita PawarUniversity of Arizona Cancer Center, University of Arizona, Tucson, AZ, United States; Department of Pharmacology, University of Arizona, Tucson, AZ, United States.
Jaime M GardUniversity of Arizona Cancer Center, University of Arizona, Tucson, AZ, United States.
Raymond B NagleUniversity of Arizona Cancer Center, University of Arizona, Tucson, AZ, United States; Department of Pathology, University of Arizona, Tucson, AZ, United States.
Anne E CressUniversity of Arizona Cancer Center, University of Arizona, Tucson, AZ, United States; Department of Cellular and Molecular Medicine, University of Arizona, Tucson, AZ, United States. Electronic address: acress@azcc.arizona.edu.
University of Arizona Cancer CenterUniversity of Arizona · US

Funding

VITAMIN AP30CA023074 · NCI · UNIVERSITY OF ARIZONA · PI Dan Theodorescu · 1985 to 2026
$110.2M
UCSD/SDSU IRACDAK12GM068524 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI TREJO, JOANN · 2003 to 2025
$24.4M
Human Prostate Cancer Metastasis and Laminin Binding IntegrinsR01CA159406 · NCI · UNIVERSITY OF ARIZONA · PI CRESS, ANNE E · 2011 to 2015
$1.5M
NCI NIH HHS 1R01 CA159406NCI NIH HHS CA23074NCI NIH HHS P30 CA023074NCI NIH HHS R01 CA159406NIGMS NIH HHS K12 GM068524
6 · The paper itself

Abstract

Cancer metastasis is a multi-step process in which tumor cells gain the ability to invade beyond the primary tumor and colonize distant sites. The mechanisms regulating the metastatic process confer changes to cell adhesion receptors including the integrin family of receptors. Our group previously discovered that the α6 integrin (ITGA6/CD49f) is post translationally modified by urokinase plasminogen activator (uPA) and its receptor, urokinase plasminogen activator receptor (uPAR), to form the variant ITGA6p. This variant of ITGA6 is a cleaved form of the receptor that lacks the ligand-binding domain. Although it is established that the uPA/uPAR axis drives ITGA6 cleavage, the mechanisms regulating cleavage have not been defined. Intracellular integrin dependent "inside-out" signaling is a major regulator of integrin function and the uPA/uPAR axis. We hypothesized that intracellular signaling molecules play a role in formation of ITGA6p to promote cell migration during cancer metastasis. In order to test our hypothesis, DU145 and PC3B1 prostate cancer and MDA-MB-231 breast cancer cell lines were treated with small interfering RNA targeting actin and the intracellular signaling regulators focal adhesion kinase (FAK), integrin linked kinase (ILK), and paxillin. The results demonstrated that inhibition of actin, FAK, and ILK expression resulted in significantly increased uPAR expression and ITGA6p production. Inhibition of actin increased ITGA6p, although inhibition of paxillin did not affect ITGA6p formation. Taken together, these results suggest that FAK and ILK dependent "inside-out" signaling, and actin dynamics regulate extracellular production of ITGA6p and the aggressive phenotype.

Indexed as

ActinsBreastBreast NeoplasmsCell Line, TumorCell MovementFemaleFocal Adhesion Protein-Tyrosine KinasesGene Expression Regulation, NeoplasticGenetic VariationHumansIntegrin alpha6MaleNeoplasm InvasivenessProstateProstatic NeoplasmsProtein Serine-Threonine KinasesActinsFocal Adhesion Protein-Tyrosine KinasesIntegrin alpha6ITGA6 protein, humanProtein Serine-Threonine KinasesReceptors, Urokinase Plasminogen ActivatorRNA, Small InterferingScaffold Protein ILKActinCancerFocal adhesion kinaseIntegrin linked kinaseITGA6uPAR

Identifiers

PMID25450398
PMCPMC4254650
OpenAlexW2006109675

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.